Pasar al contenido principal

NUEVAS ESTRATEGIAS PARA VACUNAS RECOMBINANTES OPTIMIZADAS CONTRA LA LENGUA AZUL

PID2021-128466OR-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of β2 microglobulin, the product of B2M gene, as a Host Factor for Vaccinia Virus Infection by Genome-Wide CRISPR genetic screens

  • Matía, Alejandro
  • Lorenzo, María M.
  • Romero-Estremera, Yolimar C.
  • Sánchez-Puig Eyre, Juana María
  • Zaballos, Angel
  • Blasco, Rafael
30 Pág., Genome-wide genetic screens are powerful tools to identify genes that act as host factors of viruses. We have applied this technique to analyze the infection of HeLa cells by Vaccinia virus, in an attempt to find genes necessary for infection. Infection of cell populations harboring single gene inactivations resulted in no surviving cells, suggesting that no single gene knock-out was able to provide complete resistance to Vaccinia virus and thus allow cells to survive infection. In the absence of an absolute infection blockage, we explored if some gene inactivations could provide partial protection leading to a reduced probability of infection. Multiple experiments using modified screening procedures involving replication restricted viruses led to the identification of multiple genes whose inactivation potentially increase resistance to infection and therefore cell survival. As expected, significant gene hits were related to proteins known to act in virus entry, such as ITGB1 and AXL as well as genes belonging to their downstream related pathways. Additionally, we consistently found β2-microglobulin, encoded by the B2M gene, among the screening top hits, a novel finding that was further explored. Inactivation of B2M resulted in 54% and 91% reduced VV infection efficiency in HeLa and HAP1 cell lines respectively. In the absence of B2M, while virus binding to the cells was unaffected, virus internalization and early gene expression were significantly diminished. These results point to β2-microglobulin as a relevant factor in the Vaccinia virus entry process., This work was supported by grants E-RTA2014-00006, RTA2017-0066 and PID2021-128466OR-I00 funded by Ministerio de Ciencia e Innovacion MCIN/AEI/10.13039/501100011033 aspart of the Plan Estatal de Investigacion Cientıfica,Desarrollo e Innovacion (https://www.ciencia.gob.es) to R.B. A.M. was recipient of a predoctoral, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models

  • Lorenzo, María M.
  • Marín-López, A.
  • Chiem, Kevin
  • Jiménez-Cabello, L.
  • Ullah, Irfan
  • Utrilla-Trigo, S.
  • Calvo Pinilla, Eva María
  • Lorenzo, Gema
  • Moreno, Sandra
  • Ye, Chengjin
  • Park, Jun-Gyu
  • Matía, Alejandro
  • Brun Torres, Alejandro
  • Sánchez-Puig Eyre, Juana María
  • Nogales, Aitor
  • Mothes, Walther
  • Uchil, Pradeep D.
  • Kumar, Priti
  • Ortego, Javier
  • Fikrig, Erol
  • Martínez-Sobrido, Luis
  • Blasco Lozano, Rafael
24 Pág., The COVID-19 pandemic has underscored the importance of swift responses and the necessity of dependable technologies for vaccine development. Our team previously developed a fast cloning system for the modified vaccinia virus Ankara (MVA) vaccine platform. In this study, we reported on the construction and preclinical testing of a recombinant MVA vaccine obtained using this system. We obtained recombinant MVA expressing the unmodified full-length SARS-CoV-2 spike (S) protein containing the D614G amino-acid substitution (MVA-Sdg) and a version expressing a modified S protein containing amino-acid substitutions designed to stabilize the protein a in a pre-fusion conformation (MVA-Spf). S protein expressed by MVA-Sdg was found to be expressed and was correctly processed and transported to the cell surface, where it efficiently produced cell-cell fusion. Version Spf, however, was not proteolytically processed, and despite being transported to the plasma membrane, it failed to induce cell-cell fusion. We assessed both vaccine candidates in prime-boost regimens in the susceptible transgenic K18-human angiotensin-converting enzyme 2 (K18-hACE2) in mice and in golden Syrian hamsters. Robust immunity and protection from disease was induced with either vaccine in both animal models. Remarkably, the MVA-Spf vaccine candidate produced higher levels of antibodies, a stronger T cell response, and a higher degree of protection from challenge. In addition, the level of SARS-CoV-2 in the brain of MVA-Spf inoculated mice was decreased to undetectable levels. Those results add to our current experience and range of vaccine vectors and technologies for developing a safe and effective COVID-19 vaccine., This research was funded by Instituto de Salud Carlos III, Fondo COVID-19 de proyectos de investigación sobre SARS-CoV-2 y la enfermedad COVID-19 grant COV20/00901, and grant PID2021-128466OR-I00 funded by funded by MCIN/AEI/10.13039/501100011033 as part of Plan Estatal de Investigación Científica, Desarrollo e Innovación. This research work was also funded by the European Commission—NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global). All experiments using bioluminescent imaging approach were supported by NIH grant to WM. Research on SARS-CoV-2 in L.M-S laboratory was partially supported by the San Antonio Partnership for Precision Therapeutics, the San Antonio Medical Foundation, and the Texas Biomedical Research Institute Forum Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of In Vitro Inhibitors of Monkeypox Replication

  • Chiem, Kevin
  • Nogales, Aitor
  • Lorenzo, María M.
  • Morales Vasquez, Desarey
  • Xiang, Yan
  • Gupta, Yogesh Kumar
  • Blasco, Rafael
  • de la Torre, J. C.
  • Martínez-Sobrido, Luis
15 Pág., Monkeypox virus (MPXV) infections in humans have historically been restricted to regions of endemicity in Africa. However, in 2022, an alarming number of MPXV cases were reported globally, with evidence of person-to-person transmission. Because of this, the World Health Organization (WHO) declared the MPXV outbreak a public health emergency of international concern. The supply of MPXV vaccines is limited, and only two antivirals, tecovirimat and brincidofovir, approved by the U.S. Food and Drug Administration (FDA) for the treatment of smallpox, are currently available for the treatment of MPXV infection. Here, we evaluated 19 compounds previously shown to inhibit different RNA viruses for their ability to inhibit orthopoxvirus infections. We first used recombinant vaccinia virus (rVACV) expressing fluorescence (mScarlet or green fluorescent protein [GFP]) and luciferase (Nluc) reporter genes to identify compounds with antiorthopoxvirus activity. Seven compounds from the ReFRAME library (antimycin A, mycophenolic acid, AVN-944, pyrazofurin, mycophenolate mofetil, azaribine, and brequinar) and six compounds from the NPC library (buparvaquone, valinomycin, narasin, monensin, rotenone, and mubritinib) showed inhibitory activity against rVACV. Notably, the anti-VACV activity of some of the compounds in the ReFRAME library (antimycin A, mycophenolic acid, AVN-944, mycophenolate mofetil, and brequinar) and all the compounds from the NPC library (buparvaquone, valinomycin, narasin, monensin, rotenone, and mubritinib) were confirmed with MPXV, demonstrating their inhibitory activity in vitro against two orthopoxviruses. IMPORTANCE Despite the eradication of smallpox, some orthopoxviruses remain important human pathogens, as exemplified by the recent 2022 monkeypox virus (MPXV) outbreak. Although smallpox vaccines are effective against MPXV, access to those vaccines is limited. In addition, current antiviral treatment against MPXV infections is limited to the use of the FDA-approved drugs tecovirimat and brincidofovir. Thus, there is an urgent need to identify novel antivirals for the treatment of MPXV infection and other potentially zoonotic orthopoxvirus infections. Here, we show that 13 compounds, derived from two different libraries, previously found to inhibit several RNA viruses, also inhibit VACV. Notably, 11 compounds also displayed inhibitory activity against MPXV., This work was partly supported by grant PID2021-128466OR-I00 funded by MCIN/AEI/10.13039/501100011033 to M.L. and R.B. Research in L.M.-S.’s laboratory is partially funded by the Antiviral Countermeasures Development Center, AC/DC (1U19AI171403-01); the Center for Antiviral Medicines & Pandemic Preparedness, CAMPP (1U19AI171443-01), and the QCRG Pandemic Response Program (1U19AI171110-01), three of the National Institutes of Health (NIH) funded Antiviral Drug Discovery Centers for Pathogens of Pandemic Concern; by grants W81XWH2110103, W81XWH2110095, W81XWH1910496, and W81XWH2210283 from the Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP); R43AI165089, R01AI161363, R01AI161175, R01AI145332, R01AI142985, R01AI141607, R21 AI173816, and 75N95022P00510 from the National Institutes of Health (NIH); the Center for Research on Influenza Pathogenesis (CRIP), one of the National Institute of Allergy and Infectious Diseases (NIAID) funded Centers of Excellence for Influenza Research and Response (CEIRR; contract # 75N93021C00014); the a Systems Biology Lens (SYBIL; U19AI135972); the San Antonio Partnership for Precision Therapeutics, the San Antonio Medical Foundation, and the Texas Biomedical Research Institute Forum Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evaluation of Vaccinia Virus Infection in Mice Using Two-Reporter Recombinant Virus

  • Nogales, Aitor
  • Chiem, Kevin
  • Lorenzo Gilsanz, María Mar
  • Rangel-Moreno, Javier
  • Garcia-Hernandez, Maria De La Luz
  • Park, Jun-Gyu
  • Blasco Lozano, Rafael
  • Martínez-Sobrido, Luis
The family Poxviridae comprises multiple viruses with large double-stranded (ds) DNA genomes that can infect numerous vertebrate and invertebrate hosts, including humans. The development of genetic engineering methods for Vaccinia virus (VACV), the prototypic member in the family, have allowed the manipulation of the genomes of poxviruses for the generation of recombinant (r)VACV expressing easily traceable luciferase and/or fluorescent reporter genes. These recombinant viruses have significantly contributed to progress in the field of poxvirus research and accelerated the development of novel prophylactic vaccines and therapeutic antiviral treatments. Recently, we described two reporter rVACV expressing luciferase (Nluc) and fluorescent (GFP or Scarlet) proteins to easily track viral infections in different systems, overcoming the limitations associated with the use of rVACV expressing a single luciferase or fluorescent reporter gene. Here, we describe the experimental procedures to carry out in vitro, in vivo and ex vivo studies using these novel bireporter-expressing rVACV, which also represent an excellent option to study the biology of VACV, including the use of these reporter viruses for testing new antivirals and vaccines, using cultured cells and/or well-characterized animal models of infection., Research in L.M.-S on VACV was funded by the startup funding from the Department of Microbiology and Immunology at University of Rochester. Research in R.B. group was funded by grant PID2021-128466OR-I00 from Ministerio de Ciencia eInnovación MCIN/AEI/10.13039/501100011033 as part of the Plan Estatal de Investigación Científica, Desarrollo e Innovación (https://www.ciencia.gob.es)., Peer reviewed